Familial Adenomatous PolyposisSymptoms, Doctors, Treatments, Advances & More
Learn About Familial Adenomatous Polyposis
Familial adenomatous polyposis (FAP) is an inherited disorder that is characterized by a greatly increased risk of cancer of the large intestine (colon) and rectum (collectively known as colorectal cancer). People with FAP have multiple precancerous (benign) growths (polyps) in the colon, and one or more of these polyps will likely develop into colorectal cancer. There are two forms of FAP: the classic type and the attenuated type.
Variants (also called mutations) in the APC gene cause FAP. The APC gene provides instructions for making a protein that acts as a tumor suppressor, which means that it keeps cells from growing and dividing too fast or in an uncontrolled way. In particular, the APC protein helps block a signaling pathway that promotes cell growth and division. The APC protein also interacts with parts of the cell to help ensure that the number of chromosomes in a cell is correct after the cell divides.
FAP has an incidence of 1 in 8,500 individuals. FAP accounts for about 0.5 percent of all cases of colorectal cancer.
FAP is inherited in an autosomal dominant pattern, which means one copy of the altered APC gene in each cell is sufficient to cause the disorder. Affected individuals have a 50 percent chance of passing on the APC gene variant to each child. In 75 to 80 percent of cases, an affected person has one parent with FAP.
Virginia Mason Medical Center
Gautam Mankaney, MD, is a board-certified gastroenterologist who specializes in hereditary cancer syndromes (lynch syndrome, familial adenomatous polyposis, PTEN-tumor hamartoma syndromes, juvenile polyposis, Peutz-Jeghers, Li-Fraumeni, MutYH-associated polyposis, sessile serrated polyposis), fecal microbiota transplantation, endoscopy, gastroenterology and gastrointestinal cancer.Dr. Mankaney has a special medical interest in treating individuals with a personal or family history of a hereditary cancer syndrome, or at high risk for developing cancer.Dr. Mankaney serves as both the Director of Endoscopy and Director of Gastrointestinal Cancer Prevention. Previously, he has served as a Committee Chair for the Collaborative Group of Americas on Inherited Gastrointestinal Syndromes, and as a Training Committee member with the American College of Gastroenterology. He has received multiple teaching awards.Away from work, he enjoys tennis, bouldering, hiking and traveling. Dr. Mankaney is rated as an Elite provider by MediFind in the treatment of Familial Adenomatous Polyposis. He is also highly rated in 5 other conditions, according to our data. His clinical expertise encompasses Familial Adenomatous Polyposis, Stomach Cancer, Colorectal Cancer, Colonoscopy, and Endoscopy. Dr. Mankaney is board certified in American Board Of Internal Medicine, Subspecialty In Gastroenterology. Dr. Mankaney is currently accepting new patients.
Fairview Medical Office Building
Toms Augustin is a General Surgeon practicing medicine in Cleveland, Ohio. Dr. Augustin is rated as an Elite provider by MediFind in the treatment of Familial Adenomatous Polyposis. He is also highly rated in 37 other conditions, according to our data. His clinical expertise encompasses Familial Adenomatous Polyposis, Pancreatic Cancer, Gallbladder Disease, Gallbladder Removal, and Pancreatectomy. Dr. Augustin is board certified in American Board Of Surgery, 2012.
ETSU Physicians & Associates- Gastroenterology
Mark Young is a Gastroenterologist practicing medicine in Johnson City, Tennessee. Dr. Young is rated as a Distinguished provider by MediFind in the treatment of Familial Adenomatous Polyposis. He is also highly rated in 74 other conditions, according to our data. His clinical expertise encompasses Jaundice, Acute Pancreatitis, Choledocholithiasis, Endoscopy, and Gastrectomy. Dr. Young is board certified in American Board Of Internal Medicine.
Summary: NOTE: This is a research study and is not meant to be a substitute for clinical genetic testing. Families may never receive results from the study or may receive results many years from the time they enroll. If you are interested in clinical testing please consider seeing a local genetic counselor or other genetics professional. If you have already had clinical genetic testing and meet eligibility...
Summary: The purpose of this phase I trial is to test the safety and cancer preventive effects of different doses of ONC201 in people with familial adenomatous polyposis (FAP) or a history of multiple polyps. People with familial adenomatous polyposis (FAP) or a history of multiple polyps are at higher than average risk of developing colorectal cancer. ONC201, now known as dordaviprone, is a drug that may ...
Published Date: August 26, 2025
Published By: National Institutes of Health